U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07349849) titled 'Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies' on Dec. 19, 2025.
Brief Summary: Malignant hematological tumors mainly derived from adult B cells are mainly acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL). Overall, although existing therapies have significantly improved the survival rates of most patients, the treatment of relapsed/refractory patients still faces significant challenges. CD19 is one of the most clinically valuable targets for B-cell malignant hematological tumors.
The advent of COVID-19 vaccine has brought LNP mRNA technology into the public'...